Fireside Chat with Paul Edick – Xeris Biopharma – $XERS

Fireside chat with Paul Edick – CEO of Xeris Biopharma – $XERS

What Lies Ahead For Xeris Biopharma In 2022

Jan. 1 PDUFA for Recorlev, Merck collaboration, Levothyroxine Phase 1, EIH Phase 2, and growing sales for Gvoke and Keveyis; Xeris has great potential for 2022.

Xeris enters into $71M Olguo commercialization agreement with Tetris Pharma

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe Up to $71 million in time- and milestone-based payments, plus royalties on sales Agreement covers 32 countries First launch expected in Q4 2021 in UKJuly 19, 2021 08:00 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq:…